What is the shelf life of eculizumab?

Mar 18, 2025 ... How is Soliris administered in myasthenia gravis? · 900 mg weekly for the first four weeks · 1,200 mg in the fifth week · 1,200 mg every other ... Sep 19, 2021 ... Eculizumab is an anti-C5 humanized monoclonal antibody that binds to C5, preventing its cleavage into C5a and C5b. Aug 10, 2021 ... This review presents a discussion on the therapeutic efficacy and tolerability of eculizumab in patients with MG and a summary on relevant pharmacological data. Eculizumab ... Not to be confused with ocrelizumab. Eculizumab, sold under the brand name Soliris among others, is a recombinant humanized monoclonal antibody ... eculizumab ... A drug used to prevent red blood cells from being destroyed in patients with a rare red blood cell disorder called paroxysmal nocturnal ... Aetna considers eculizumab, or its biosimilar, medically necessary for any of the following indications when criteria are met: It is used by specialist doctors to treat two rare conditions called paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic-uraemic syndrome (aHUS). Oct 24, 2017 ... The US Food and Drug Administration (FDA) approved eculizumab as a treatment for adult patients with generalized myasthenia gravis (gMG) who are anti- ... Apr 10, 2019 ... Eculizumab (Soliris®, Alexion Pharmaceuticals, Inc., Boston, MA, USA) ... Soliris (eculizumab) [prescribing information]. Boston, MA ... Soliris was approved by the U.S. Food and Drug Administration in 2019 for the treatment of adults with NMOSD who are positive for anti-AQP4 antibodies. The ...